AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax

Soon Khai Low, Suparna Nanua, Mehul Patel, Anne S. Renteria

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

A patient with history of myelodysplastic syndrome (MDS) presented with multifocal pneumonia and was found to have Philadelphia chromosomepositive (Ph+) acute myeloid leukemia (AML). A tyrosine kinase inhibitor (TKI) was added to decitabine and venetoclax combination, providing a molecular and cytogenetic complete response despite additional cytogenetic and molecular abnormalities. She remains in remission after eleven cycles of treatment. Our report describes the tolerability and success of a triplet regimen that incorporates a TKI to a backbone of decitabine and venetoclax in a patient with high-risk disease and with significant comorbidities.

Original languageEnglish
Article number100333
JournalLeukemia Research Reports
Volume17
DOIs
StatePublished - Jan 2022
Externally publishedYes

Keywords

  • Acute myeloid leukemia
  • Decitabine
  • Philadelphia chromosoome
  • Tyrosine kinase inhibitor
  • Venetoclax

Fingerprint

Dive into the research topics of 'AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax'. Together they form a unique fingerprint.

Cite this